SEC Form 4 · accession 0001209191-16-106218
Tobira Therapeutics, Inc. · TBRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
A/S Novo
10% Owner
Period of report
Mar 2, 2016
Accepted (ET)
Mar 4, 2016 · 6:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001311596
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 2, 2016 | S | 110,000 | $6.9184 | D | 2,361,405 | D | |
| Common StockF2 | Mar 3, 2016 | S | 25,000 | $6.8558 | D | 2,336,405 | D | |
| Common StockF3 | Mar 4, 2016 | S | 55,000 | $6.5394 | D | 2,281,405 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.77 to $7.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.75 to $6.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.50 to $6.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.